Editorial: Advancing cancer therapy: innovative strategies targeting immune evasion and metabolic modulation.
作者信息
Fernandes Mónica Teotónio, De Sousa-Coelho Ana Luísa, Méndez-Lucas Andrés
机构信息
Escola Superior de Saúde, Universidade do Algarve (ESSUAlg), Faro, Portugal.
Algarve Biomedical Center Research Institute (ABC-Ri), Universidade do Algarve (UAlg), Faro, Portugal.
出版信息
Front Med (Lausanne). 2025 Aug 29;12:1677300. doi: 10.3389/fmed.2025.1677300. eCollection 2025.
Abstract
摘要
相似文献
1
Editorial: Advancing cancer therapy: innovative strategies targeting immune evasion and metabolic modulation.社论：推进癌症治疗：针对免疫逃逸和代谢调节的创新策略
Front Med (Lausanne). 2025 Aug 29;12:1677300. doi: 10.3389/fmed.2025.1677300. eCollection 2025.
2
Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies.胆管癌的免疫治疗：重塑肿瘤微环境与推进精准联合策略
Front Immunol. 2025 Aug 8;16:1651769. doi: 10.3389/fimmu.2025.1651769. eCollection 2025.
3
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.癌症中的免疫逃逸：机制与前沿治疗方法。
Signal Transduct Target Ther. 2025 Jul 31;10(1):227. doi: 10.1038/s41392-025-02280-1.
4
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance.癌症免疫治疗耐药的机制、联合治疗及生物标志物。
Cell Commun Signal. 2024 Jun 19;22(1):338. doi: 10.1186/s12964-024-01711-w.
5
Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.人类前列腺癌的免疫景观：免疫逃逸机制和个性化免疫治疗的生物标志物。
BMC Cancer. 2020 Jun 18;20(1):572. doi: 10.1186/s12885-020-07058-y.
6
Subgrouping breast cancer patients based on immune evasion mechanisms unravels a high involvement of transforming growth factor-beta and decoy receptor 3.基于免疫逃逸机制对乳腺癌患者进行亚组分类，揭示转化生长因子-β和诱饵受体 3 的高参与度。
PLoS One. 2018 Dec 4;13(12):e0207799. doi: 10.1371/journal.pone.0207799. eCollection 2018.
7
Unraveling the immune evasion mechanisms in the tumor microenvironment of head and neck squamous cell carcinoma.解析头颈部鳞状细胞癌肿瘤微环境中的免疫逃逸机制。
Front Immunol. 2025 May 14;16:1597202. doi: 10.3389/fimmu.2025.1597202. eCollection 2025.
8
Metabolic alterations driven by LDHA in CD8 + T cells promote immune evasion and therapy resistance in NSCLC.乳酸脱氢酶A（LDHA）驱动的CD8 + T细胞代谢改变促进非小细胞肺癌（NSCLC）的免疫逃逸和治疗抵抗。
Sci Rep. 2025 Jul 8;15(1):24440. doi: 10.1038/s41598-025-87361-5.
9
Cancer stem cells in personalized therapy: mechanisms, microenvironment crosstalk, and therapeutic vulnerabilities.个性化治疗中的癌症干细胞：机制、微环境相互作用及治疗弱点
Front Cell Dev Biol. 2025 Jul 30;13:1619597. doi: 10.3389/fcell.2025.1619597. eCollection 2025.
10
Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies.癌症中的免疫原性细胞死亡与代谢重编程：机制、协同作用及创新治疗策略
Biomedicines. 2025 Apr 12;13(4):950. doi: 10.3390/biomedicines13040950.
本文引用的文献
1
Cancer statistics, 2025.2025年癌症统计数据。
CA Cancer J Clin. 2025 Jan-Feb;75(1):10-45. doi: 10.3322/caac.21871. Epub 2025 Jan 16.
2
Tumor-induced metabolic immunosuppression: Mechanisms and therapeutic targets.肿瘤诱导的代谢性免疫抑制：机制与治疗靶点。
Cell Rep. 2025 Jan 28;44(1):115206. doi: 10.1016/j.celrep.2024.115206. Epub 2025 Jan 10.
3
Human T cell glycosylation and implications on immune therapy for cancer.人类 T 细胞糖基化及其对癌症免疫治疗的影响。
Hum Vaccin Immunother. 2020 Oct 2;16(10):2374-2388. doi: 10.1080/21645515.2020.1730658. Epub 2020 Mar 18.
4
Understanding the tumor immune microenvironment (TIME) for effective therapy.理解肿瘤免疫微环境（TIME）以实现有效的治疗。
Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23.
5
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.癌症免疫疗法的原发性、适应性和获得性耐药性。
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
6
The Emerging Hallmarks of Cancer Metabolism.癌症代谢的新特征
Cell Metab. 2016 Jan 12;23(1):27-47. doi: 10.1016/j.cmet.2015.12.006.
7
Hallmarks of cancer: the next generation.癌症的特征：下一代。
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
Zotero 插件